Abstract: In recent years, psychotropic drug use among children and adolescents in Europe and USA has increased. However, the majority of psychotropic drugs are not formally approved for use in children and adolescents, and consequently, use is often off-label. The objectives were to describe time trends in off-label prescribing rates and the most commonly used types of psychotropic drugs by age and gender in Danish children and adolescents. Using the Register of Medicinal Product Statistics, we identified all prescriptions for sedatives, hypnotics and antidepressants filled for children and adolescents in 2006-2012. Information on diagnoses was obtained from the Danish National Registry of Patients and allowed classification of prescriptions as either on-or off-label. We identified 186,831 prescriptions filled for 29,851 children and adolescents: 88.0% of these were classified as off-label. During 2006-2012, off-label rates for sedatives and hypnotics increased significantly, except for prescriptions for girls aged 15-17 years [range 24.1-98.2% (girls), 31.9% to 99.0% (boys)]. In the same period, the number of registered melatonin prescriptions (all off-label) increased expansively. For antidepressants, we found decreasing trends in off-label rates over time [range 94.5-65.6% (girls), 93.8-71.2% (boys)]. Off-label prescribing of psychotropic drugs to Danish children and adolescents is common. Off-label rates for sedatives and hypnotics increased in the period of 2006-2012, whereas off-label rates for antidepressants declined. Off-label rates might be underestimated and should be considered a conservative estimate.
The use of psychotropic drugs for the treatment of psychiatric disorders in children and adolescents is common and has, in the last two decades, increased several times in western countries [1] [2] [3] . In Denmark, in particular the use of melatonin [4] and selective serotonin reuptake inhibitors (SSRIs) [5] has increased: a recent large cross-sectional study showed a marked increase in the use of antidepressants during 2005-2012 in Denmark, Germany, the Netherlands, the United Kingdom and in the United States. Notably, the largest increase during this period was observed in Denmark where use of antidepressants in children increased by 60.5% (from 0.6% to 1%) compared to, for example, 17.6% (0.5-0.6%) in the Netherlands [6] .
The majority of psychotropic drugs are not formally approved for use in children and adolescents and consequently the use will often be off-label [7] [8] [9] [10] [11] [12] , meaning that the drugs are used outside the by-authority approved specifications regarding age, indication, dose, route of administration and duration of treatment. In Denmark, the physician has the authority to prescribe drugs off-label [13] , but in the case of off-label prescribing, the physician, and not the pharmaceutical company, has the sole responsibility if, for example, adverse events occur [14] . Offlabel use may, however, be associated with a higher risk of adverse effects in adults [15] . If this association is also present in children, high off-label rates might infer an increased risk of adverse events. It is, however, required by the Danish health authorities that only specialists in child and adolescent psychiatry prescribe these drugs for children and adolescents [16] .
To our knowledge, rates of off-label psychotropic drug use in children and adolescents in Denmark have only previously been studied in a hospital chart review which showed that especially antipsychotics, antidepressants and sedatives were used off-label [17] . However, this study was restricted to a sample of 503 children treated at two highly specialized outpatient clinics, thus limiting the generalizability to the overall population. The Danish nationwide health registers pose a unique opportunity to expand the study of off-label use to an entire nation. We therefore conducted a nationwide drug utilization study based on these registers.
We aimed to explore the time trends in off-label prescribing of sedatives, hypnotics and antidepressants in children and adolescents during 2006-2012. In addition, we also sought to study variation by gender, age and drug type. Finally, we aimed to explore the most commonly used drugs and the most frequent psychiatric conditions associated with on-or off-label prescribing.
Methods
Design. We conducted a nationwide, register-based drug utilization study, examining rates for off-label use of sedatives, hypnotics and antidepressants filled for Danish children and adolescents from 2006 to 2012.
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Setting. In Denmark, the public healthcare system provides free-ofcharge services to all 5.6 million Danish citizens, including the 1.2 million Danes under the age of 18 years [18] . This includes all services for child and adolescent psychiatry. In 2010, it was estimated that approximately 20% of adult patients referred to psychiatric treatment in Denmark were treated by psychiatric practitioners in the private sector [19] .
Thus, the public mental health sector is responsible for the treatment of the majority of children and adolescents requiring psychiatric treatment.
Every Danish citizen is given a personal registration number (CPR number [20] ), a unique personal identifier, which is used in every national health registry and allows linkage between the registers.
Data collection.
Study population and study drugs. Using the Register of Medicinal Product Statistics (RMPS), we identified all prescriptions for sedatives, hypnotics and antidepressants [Anatomical Therapeutic Classification (ATC) group N05C and N06A] dispensed to children and adolescents (<18 years at the date of dispensing) in the period of 1 January 2006 till 31 December 2012. In the following, these drugs will be termed study drugs (see Tables S1 and S4 for approved and most used drugs, respectively). The registry contains information (e.g. ATC code, date of prescription and CPR number of the patient) on all prescriptions filled at Danish community pharmacies since 1995 [21] .
Data from other registries. The Danish Civil Registration System [20] was established in 1968 and comprises all Danish residents. The register contains information on date of birth and gender and allowed us to calculate age at the time of filling a prescription and to look at gender differences.
The Danish National Registry of Patients (DNRP) [22] was established in 1977 and includes information (e.g. diagnosis according to International Classification of Diseases (ICD-10, from 1995 [23] ) on all inpatient visits related to somatic contacts. Information on visits in outpatient clinics, emergency room contacts and psychiatric contacts has been included since 1995. Through this register, we recorded if the children and adolescents receiving sedatives, hypnotics or antidepressants had a diagnosis for which the given drug was approved.
The National Health Insurance Service Registry (NHISR) [24] contains information on services provided by primary healthcare practitioners, for example general practitioners, dentists, psychologists and other medical specialists, including private specialists in child and adolescent psychiatry, since 1990. The register is purely administrative and does not contain any diagnoses or additional clinical information. We used this register to check whether the children and adolescents received services from private practitioners in child and adolescent psychiatry.
Classification of on-label and off-label use: We classified all prescriptions of the study drugs as either on-label or off-label. Information on a drug's approval status in terms of age and therapeutic indication was obtained from the Summary of Product Characteristics (SmPCs) of the innovator drug for each drug. If no innovator drug existed, the SmPC from the newest, non-parallel-imported drug was used. Information from the SmPC sections 4.1 Therapeutic indications, 4.2 Posology and method of administration, 4.3 Contraindications and 4.4 Special warnings and precautions for use defined the off-label definition for the specific drug. If the SmPC held no information about paediatric use, we assumed that the drug was not approved for use in children and adolescents. We used the SmPCs available in spring 2014 and checked for changes during the study period. The only labelling change observed was for fluoxetine, which received paediatric indication in August 2007 in Denmark. The therapeutic indication from the SmPC was translated into ICD-10 codes (Table S1) .
A prescription was classified as on-label, when the drug was used within the approved age category and for the approved indication(s). Meanwhile, we defined two levels of off-label use, that is off-label by age and off-label by indication, collectively referred to as off-label. A prescription was classified as off-label by age if the drug was used beyond the approved age category at the time of drug dispensing regardless of whether the child had the approved indication. We defined a prescription as being off-label by indication, if the child did not have a diagnosis registered in DNRP at the time of dispensing or up to 12 months after, for which the drug was approved. The delay of 12 months was allowed to account for potential delays in the diagnostic process. 'Off-label by indication' was only assessed whether the prescription was used within the approved age category at the time of dispensing ( fig. 1 ). We did not assess whether prescriptions were onor off-label by dose, duration of treatment or route of administration, as information from registries regarding this was not available.
Statistical analyses.
Main analysis. Prescriptions in our analysis were divided into two drug groups according to the ATC classification system. Using a binary logistic regression model, we calculated rates of off-label use for all prescriptions dispensed in each of the two drug groups. We grouped age into four categories (0-5 years, 6-11 years, 12-14 years and 15-17 years) and calculated rates of off-label use for each year in the study period for each age group and for both genders. As the denominator, we used the total number of prescriptions in the drug group filled per strata according to year, age group and gender. Because each child could fill more than one prescription per year, we used robust variance estimates to control for the lack of independency between prescriptions.
In order to test for time trends, we performed the analysis with years as a continuous variable, and thereby testing for linear trend, achieving a p-value on a trend in the rates of off-label use over the 7 years. The p-value for differences in rates of off-label use by gender was calculated for each age group and drug type using the binary regression model. The significance level was set at 0.05.
Sensitivity analysis.
As the DNRP does not contain diagnoses from private practitioners, we may overestimate the rates of off-label use. Therefore, we conducted a sensitivity analysis including data from the NHISR. In this analysis, we reclassified antidepressant prescriptions classified as off-label by indication, as being on-label if the child had received services from a private practitioner in child and adolescent psychiatry within a year before or after the date of filling the prescription. This analysis was not relevant for sedatives and hypnotics as the only approved indication for this drug group is epilepsy, which is unlikely to be diagnosed as well as treated by private practitioners.
Melatonin is sold in two preparations in Denmark: Circadin â and a special preparation produced by the local pharmacy staff. We were not able to discriminate between the two formulations in this study. As the special preparation was only systematically registered in the RMPS from 2011 and onwards, we performed a sensitivity analysis that excluded prescriptions for melatonin from the group of sedatives and hypnotics.
Additional analyses. For each age group and gender, we identified the most commonly used drugs, at the active ingredient level, classified as on-label as well as off-label in 2006 and 2012. Furthermore, we identified the most common psychiatric diagnoses [ICD-10 codes F00-F99 and G40-G41 (epilepsy)] from DNRP associated with on-or off-label use in 2012.
We performed all analyses in STATA 13. The study was approved by the Danish Data Protection Agency (Record no. 2014-41-2687). According to Danish law, no ethical approval was necessary for this study [25] .
Results
We identified a total of 186,831 prescriptions filled for 29 
Sedatives and hypnotics.
For sedatives and hypnotics, a total of 45,609 prescriptions were dispensed to 11,484 children and adolescents during 2006-2012 (42.5% girls and 57.5% boys). Median age at first prescription was 15 years for girls and 12 years for boys.
Main analysis. Overall, 94.6% (n = 43,125) prescriptions were classified as off-label; 98.4% (n = 42,425) were classified as off-label by age and 1.5% (n = 700) as off-label by indication.
Rates of off-label use of sedatives and hypnotics stratified by age, gender and year are shown in fig. 2 and Table S2 . During the period, rates of off-label use of sedatives and hypnotics ranged from 24.1% to 98.2% for girls and from 31.9% to 99.0% for boys, although with large differences in variations between different age categories, especially for girls ( fig. 2) . For both genders, we observed a significant increase in rates of off-label use from 2006 to 2012. The largest increase was observed for boys and girls aged 6-11 years, while there was no change in rates over time for off-label prescriptions for 15-to 17-year-old girls ( fig. 2) .
Sensitivity analysis. When we excluded prescriptions for melatonin, there was a tendency of decreasing rates of offlabel use during the study period. This decrease was significant for prescriptions for 6-to 11-year-olds and 15-to 17-year-olds ( fig. 3 ).
Additional analyses. Nitrazepam was the only sedative and hypnotic agent approved for use in children and adolescents, and thus the only drug used on-label. In 2006, nitrazepam was the most commonly drug used off-label in the younger age groups (<12 years), due to use in non-approved indications, that is off-label by indication, and zopiclone was the most commonly drug used off-label for the older age groups (>12 years) (table 1). In 2012, melatonin was the dominant drug used off-label in all groups (table 1) .
In 2012, epilepsy was the most common diagnosis among children and adolescents receiving a sedative and hypnotic agent classified as on-label (Table S5 ). The range of psychiatric diagnoses for children and adolescents receiving sedative and hypnotic agents classified as off-label varied between age groups; hyperkinetic disorder was the most common diagnosis for girls aged 6-14 years and boys >6 years, epilepsy was the most common diagnosis for children <6 years, while 'reaction to severe stress' was the most common diagnosis among girls aged 15-17 years (Table S6) .
Antidepressants.
A total of 141,222 prescriptions for antidepressants were filled for 20,944 children and adolescents (65.2% girls and 34.8% boys) during 2006-2012. Median age at first prescription was 16 years for girls and 15 years for boys.
Main analysis. Overall, 85.9% (n = 121,376) prescriptions were classified as off-label; of these, 60.5% (n = 73,453) were off-label by age and 39.5% (n = 47,923) were off-label by indication. The rates of off-label use varied from 65.6% to 94.5% for girls and from 71.2% to 93.8% for boys, with differences within age groups and year of prescription ( fig. 4 and Table S3 ). As no antidepressants were approved for use in children aged 0-5 years during the study period, the rate of off-label use was 100% in all years. Generally, the rates of off-label use tended to decrease during the study period and this decrease reached statistical significance for prescriptions for girls and boys aged 12-14 years and 15-17 years.
The largest decrease was observed for the age 12-14 years, for prescriptions for both genders.
Sensitivity analysis. When including services from private practitioners in child -and adolescent psychiatry in our analyses, the overall rates of off-label use decreased to 78.0%, of which 66.7% (n = 73,453) were off-label by age and 33.3% (n = 36,634) were off-label by indication. As expected, the rates of off-label use were generally lower than in the main analysis and with the same trend in decreasing rates of off-label use over time ( fig. 5 and Table S3 ).
Additional analyses. In 2006, sertraline was the most common antidepressant used on-label in all age groups and genders. In 2012, both sertraline and fluoxetine were the most common drugs used on-label (Tables S4 and S7) .
In 2006 and 2012, citalopram and sertraline were the drugs most often used off-label for both genders aged 6-17 years (table 1) .
In 2006, approximately 40% of prescriptions for antidepressants were for drugs not approved for use in children. In 2012, this rate declined to <20% of prescriptions of antidepressants (Table S4) . For children and adolescents of both genders receiving an on-label prescription in 2012, the most common diagnosis was obsessive-compulsive disorder (OCD) ( Table S5) for which sertraline and fluvoxamine are approved in Denmark (Table S1 ).
The most common diagnosis among girls who received an off-label prescription in 2012 was depression (858, 16.7%) (only fluoxetine and imipramine are approved to treat depressive children in Denmark -see Table S1 ), whereas the most common diagnosis for boys was pervasive developmental disorder (356, 11.0%) ( Table S6) .
Discussion
To our knowledge, this register-based study is the first one to systematically investigate the national rates of off-label use of sedatives, hypnotics and antidepressants. The study was performed in an unselected population of Danish children and adolescents.
We found rates of off-label use of sedatives and hypnotics around 40% in children and adolescents aged 0-14 years in 2006, and these rates rose to almost 100% in all age groups in 2012, explained by an increased registration and/or use of melatonin. For 15-to 17-year-olds, we observed no or only a small increase in rates of off-label use over time, as the rate of off-label use was high already in 2006, due to use of zopiclone. The rate of off-label use did not rise, rather declined, when we excluded melatonin from the analysis. During the entire study period, we found high overall rates of off-label use of antidepressants. However, for all age groups, we observed a tendency towards decreasing rates of off-label use over time. Inclusion of services from private practitioners in psychiatry did, however, lower the rates of off-label use, suggesting that our off-label rates could be overestimated.
In Denmark, and throughout the European Union, Circadin â is the only licensed form of melatonin and was approved for sleeping disorders in adults above 55 years of age in 2007. It is sold as a prescription drug in EU in contrast to the overthe-counter sale in, for example, Canada and the USA [26] . Use of Circadin â in children and adolescents in Denmark is thus off-label. However, for children and adolescents, a 3-mg preparation produced by the local pharmacies is often used [27] . This melatonin preparation was not systematically registered in the RMPS before 2011. As mentioned, it was not possible to distinguish between these two formulations in this study, and the increased use of sedative and hypnotic agents caused by melatonin found in this study may thus be due to improved registration of melatonin use in the RMPS rather than actual increased use of melatonin. However, a Danish report from 2015 found increased use of melatonin during our study period: the number of children who received Circadin . Off-label rates for antidepressants including data on contacts with private practitioners in child and adolescent psychiatry. Off-label rates for prescriptions for antidepressants for girls and boys from 2006 to 2012, stratified by age groups. These off-label rates include data from The National Health Insurance Service Registry (NHISR) on contacts with private practitioners in child and adolescent psychiatry. [28] . Use of locally produced melatonin is unlicensed rather than off-label. A Norwegian study investigated the prevalence of melatonin use in 2004-2012 and comorbidity for recurrent users aged 4-17 years. The prevalence of melatonin use doubled three times for boys and five times for girls during the study period. For recurrent users of melatonin, the most common diagnoses from 2008 to 2012 were hyperkinetic disorders, psychological developmental disorders and other behavioural and emotional disorders [29] . This is in accordance with our findings, that is, that hyperkinetic disorder, epilepsy and reaction to severe stress were the most common diagnoses in children and adolescents who received sedatives and hypnotics off-label, which indicates that melatonin is used as comedication. Similarly, in a chart review study conducted at a Danish department of child and adolescent psychiatry, melatonin accounted for 17% of all prescriptions and was used to treat sleeping disorders, most often as comedication in relation to another psychotropic treatment [17] . The present study confirms previous observation that melatonin is a much-preferred drug for children and adolescents, even though both efficacy and safety, especially for long-term use, are not well-described [30] .
The younger age at the first prescription for boys compared to girls may reflect differences in patterns of diagnoses and thus treatment for genders. For example, it is shown that boys with attention deficit hyperactivity disorder (ADHD) are prone to receive medical treatment at an earlier age than girls [31] .
The rates of off-label use found for antidepressants in children and adolescents in the present study are comparable to findings in studies from other western countries; Czaja et al. found an off-label prescription rate of 70% from 1997 to 2009 in the USA, based on paid healthcare insurance claims [32] . In Germany, Dorks et al. [33] reported an off-label prescription rate of 49% in 2004-2006 and Lee et al. [34] found 90% of antidepressant treatments in a US outpatient setting from 2000 to 2006 to be off-label. Further, we found increased use of antidepressants in Denmark over the study period, which is in accordance with a recent study [6] .
In the present study, we found significant time trends of falling rates of off-label use for antidepressants in both genders for the older age groups: a tendency which was also found in the German study by Dorks et al. [33] . The tendency of falling offlabel rates found in this study can be explained by a change in prescription habits towards antidepressants approved for children and adolescents (e.g. fluoxetine). As mentioned, prescriptions for antidepressants without a paediatric indication dropped from approximately 40% in 2006 to <20% in 2012. However, the fact that the off-label rates by far exceed these numbers reflects that a high proportion of the prescriptions for drugs with a paediatric indication is classified as off-label due to use in other indications and age groups than they are approved for. Such a change may be caused by increased focus on the muchdebated clinical issue of pharmacological treatment of depressed children and adolescents with SSRIs, where severe side effects such as suicidal behaviour have been suggested [35, 36] . The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) issued warnings against use of SSRIs in children and adolescents (by FDA in 2004 [37] and EMA in 2005 [38] ). Most recently, a Cochrane review and meta-analyses re-analysed data from clinical trials and showed an increased risk of suicidal and aggressive behaviour in children and adolescents receiving antidepressants compared to placebo. These findings, however, did not depend upon whether the drug was approved for treatment of children and adolescents or not [39] . Another recent review by Cipriani et al. [40] showed that fluoxetine is the only drug superior to placebo, when treating major depression disorder in children and adolescents.
It could be questioned whether exclusive use of drugs approved for children would be advantageous regarding effects and side effects. For example, the tricyclic antidepressant imipramine is approved for treatment of depression in children, but as shown in the present as well as previous studies, this drug is rarely used [6] . This most likely reflects the fact that prescribers consider the milder safety profile of non-approved antidepressants, for example sertraline and citalopram, to be more important than label status when choosing type of antidepressant therapy for children.
Several initiatives from national and international regulatory authorities have been launched with the aim to increase onlabel use of drugs in children. In 2007, the EMA introduced the 'Pediatric Investigation Plan' (PIP), a development plan with the purpose of supporting the authorization of new drugs and labelling changes for existing drugs for paediatric use when safe [41] . However, a Danish study from 2013 showed that this plan had not yet changed prescribing patterns, maybe in part because the physicians consider their existing prescribing pattern to be rational [42] . In Denmark, the National Board of Health has published guidelines that point out which antidepressants are on-label and recommend that diagnostics and initiation of treatment should be done by specialists in child and adolescent psychiatry [15, 43] .
The principal strength of this study is the comprehensive nature of the study: nationwide registers allowed us to identify all prescriptions filled for a whole population of children and adolescents for sedatives, hypnotics and antidepressants over a 7-year period.
The Danish health registries are generally known to have a high degree of completeness and validity [44] . The Danish National Prescription Registry, which is part of the RMPS, is called one of the world's most powerful pharmacoepidemiological tools, due to high validity and possibility of linkage to other registries [21] .
There are limitations as well, and some of these may have caused us to slightly underestimate the true rates of off-label use. Firstly, we only included age and indication in the offlabel classification in our study. Other criteria for off-label use are dose, route of administration and duration of treatment, which were not available and therefore not assessed in this study. However, in a prior Danish study [17] , off-label classification due to dose or duration of treatment was rare. Secondly, we assumed that a certain drug was used to treat a certain diagnosis. However, even though the child has an approved diagnosis for the drug registered in DNRP, it may not be the real treatment indication.
Diagnoses made in primary care were not available to us, and hence the rates of off-label use associated with the prescribing of antidepressants in the main analyses may be an overestimation of the true rates. To account for this, we included data on contacts with private practitioners in child and adolescent psychiatry, which reduced the rates as expected. However, as we have no clinical information on the reason behind the contact, this procedure may have resulted in an underestimation of the true off-label rates and should therefore be considered a conservative estimate of the rates of off-label use.
Conclusion
In this large nationwide register-based study exploring offlabel use of sedatives, hypnotics and antidepressants in Danish children and adolescents, we found high and increasing rates of off-label use of for sedatives and hypnotics, which were driven by melatonin. Knowledge on efficacy and safety on use of melatonin in children, especially long-term use, is highly warranted. We found high, but declining, off-label prescribing rates for antidepressants during the study period, where the overall use of antidepressants increased. Differences observed between age and genders may reflect different patterns of diagnoses and thus treatment. Regulations from EMA and greater adherence to guidelines from the National Board of Health defining which antidepressants are on-label, and strong emphasis that diagnostics and initiation of treatment should be done by specialists in child and adolescent psychiatry, may reduce off-label rates in the future.
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